Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3

  • Authors:
    • Jianliang Shen
    • Linwen Zeng
    • Liangming Pan
    • Shaofeng Yuan
    • Ming Wu
    • Xiongdong Kong
  • View Affiliations

  • Published online on: January 24, 2018     https://doi.org/10.3892/ol.2018.7851
  • Pages: 4557-4563
Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Tetramethylpyrazine (TMP), an effective component of the traditional Chinese medicine Chuanxiong Hort, has been proven to exhibit a beneficial effect in a number of types of malignant epithelial cancer. However, the mode of action of TMP on breast cancer cells remains unknown. The aim of the present study was to investigate the regulatory effect of TMP on breast cancer cells and its underlying molecular mechanism of action. Different concentrations of TMP were used to treat breast cancer cells, and subsequently, the effects on the viability, apoptosis, and migration and invasion abilities were determined. In addition, the expression and activity levels of the protein kinase B (Akt) signaling pathway and caspase‑3 were explored via reverse transcription‑quantitative polymerase chain reaction and western blot analysis. The results of the present study revealed that TMP significantly inhibited the viability, migration and invasion rates, and increased the apoptosis of MDA‑MB‑231 cells in a dose‑dependent manner. The minimum effective dose was ~1,600 µM. Additional mechanistic studies demonstrated that 1,600 and 3,200 µM TMP significantly decreased the gene expression and activity of Akt and increased the activity of caspase‑3. This mechanism may be responsible for the inhibition of viability, migration and invasion, and activation of apoptosis in breast cancer cells. The results of the present study suggested that TMP may be used in chemotherapy against breast cancer.

References

1 

Kamangar F, Dores GM and Anderson WF: Patterns of cancer incidence, mortality and prevalence across five continents: Defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 24:2137–2150. 2006. View Article : Google Scholar : PubMed/NCBI

2 

Sim X, Ali RA, Wedren S, Goh DL, Tan CS, Reilly M, Hall P and Chia KS: Ethnic differences in the time trend of female breast cancer incidence: Singapore, 1968–2002. BMC Cancer. 6:2612006. View Article : Google Scholar : PubMed/NCBI

3 

Gujam FJ, Going JJ, Edwards J, Mohammed ZM and McMillan DC: The role of lymphatic and blood vessel invasion in predicting survival and methods of detection in patients with primary operable breast cancer. Crit Rev Oncol Hematol. 89:231–241. 2014. View Article : Google Scholar : PubMed/NCBI

4 

Hack CC, Voiß P, Lange S, Paul AE, Conrad S, Dobos GJ, Beckmann MW and Kümmel S: Local and systemic therapies for breast cancer patients: Reducing Short-term symptoms with the methods of integrative medicine. Geburtshilfe Frauenheilkd. 75:675–682. 2015. View Article : Google Scholar : PubMed/NCBI

5 

Nagaraj G, Ellis MJ and Ma CX: The natural history of hormone receptor-positive breast cancer: Attempting to decipher an intriguing concept. Oncology (Williston Park). 26:696–700. 2012.PubMed/NCBI

6 

Tang Y, Wang Y, Kiani MF and Wang B: Classification, treatment strategy and associated drug resistance in breast cancer. Clin Breast Cancer. 16:335–343. 2016. View Article : Google Scholar : PubMed/NCBI

7 

Rybárová S, Hodorová I, Hajduková M, Schmidtová K, Mojzis J, Kajo K, Kviatkovská Z, Plank L, Benický M, Mirossay A, et al: Expression of MDR proteins in breast cancer and its correlation with some clinical and pathological parameters. Neoplasma. 53:128–135. 2006.PubMed/NCBI

8 

Zaragozá R, García-Trevijano ER, Lluch A, Ribas G and Viña JR: Involvement of different networks in mammary gland involution after the pregnancy/lactation cycle: Implications in breast cancer. IUBMB Life. 67:227–238. 2015. View Article : Google Scholar : PubMed/NCBI

9 

Espinoza-Fonseca LM: Targeting MDM2 by the small molecule RITA: Towards the development of new multi-target drugs against cancer. Theor Biol Med Model. 2:382005. View Article : Google Scholar : PubMed/NCBI

10 

Núñez C, Capelo JL, Igrejas G, Alfonso A, Botana LM and Lodeiro C: An overview of the effective combination therapies for the treatment of breast cancer. Biomaterials. 97:34–50. 2016. View Article : Google Scholar : PubMed/NCBI

11 

Ma P and Mumper RJ: Paclitaxel nano-delivery systems: A comprehensive review. J Nanomed Nanotechnol. 4:10001642013. View Article : Google Scholar : PubMed/NCBI

12 

Wang Y, Fu Q and Zhao W: Tetramethylpyrazine inhibits osteosarcoma cell proliferation via downregulation of NF-κB in vitro and in vivo. Mol Med Rep. 8:984–988. 2013. View Article : Google Scholar : PubMed/NCBI

13 

Li WM, Liu HT, Li XY, Wu JY, Xu G, Teng YZ, Ding ST and Yu C: The effect of tetramethylpyrazine on hydrogen peroxide-induced oxidative damage in human umbilical vein endothelial cells. Basic Clin Pharmacol Toxicol. 106:45–52. 2010.PubMed/NCBI

14 

Zheng CY, Xiao W, Zhu MX, Pan XJ, Yang ZH and Zhou SY: Inhibition of cyclooxygenase-2 by tetramethylpyrazine and its effects on A549 cell invasion and metastasis. Int J Oncol. 40:2029–2037. 2012.PubMed/NCBI

15 

Yin J, Yu C, Yang Z, He JL, Chen WJ, Liu HZ, Li WM, Liu HT and Wang YX: Tetramethylpyrazine inhibits migration of SKOV3 human ovarian carcinoma cells and decreases the expression of interleukin-8 via the ERK1/2, p38 and AP-1 signaling pathways. Oncol Rep. 26:671–679. 2011.PubMed/NCBI

16 

Wang XB, Wang SS, Zhang QF, Liu M, Li HL, Liu Y, Wang JN, Zheng F, Guo LY and Xiang JZ: Inhibition of tetramethylpyrazine on P-gp, MRP2, MRP3 and MRP5 in multidrug resistant human hepatocellular carcinoma cells. Oncol Rep. 23:211–215. 2010.PubMed/NCBI

17 

Zhang Y, Liu X, Zuo T, Liu Y and Zhang JH: Tetramethylpyrazine reverses multidrug resistance in breast cancer cells through regulating the expression and function of P-glycoprotein. Med Oncol. 29:534–538. 2012. View Article : Google Scholar : PubMed/NCBI

18 

Zhang P, Zheng BB, Wang HY, Chen JH, Liu XY and Guo XL: DLJ14, a novel chemo-sensitization agent, enhances therapeutic effects of adriamycin against MCF-7/A cells both in vitro and in vivo. J Pharm Pharmacol. 66:398–407. 2014. View Article : Google Scholar : PubMed/NCBI

19 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

20 

Tang ZY, Wang SL and Lin Y: Progress in the pharmacokinetics and clinical pharmacodynamics of tetramethylpyrazine in nervous system. Chin J Clin Pharmacol. 26:535–539. 2010.

21 

Fu YS, Lin YY, Chou SC, Tsai TH, Kao LS, Hsu SY, Cheng FC, Shih YH, Cheng H, Fu YY and Wang JY: Tetramethylpyrazine inhibits activities of glioma cells and glutamate neuro-excitotoxicity: Potential therapeutic application for treatment of gliomas. Neuro Oncol. 10:139–152. 2008. View Article : Google Scholar : PubMed/NCBI

22 

Chen L, Lu Y, Wu JM, Xu B, Zhang LJ, Gao M, Zheng SZ, Wang AY, Zhang CB, Zhang WW and Lei N: Ligustrazine inhibits B16F10 melanoma metastasis and suppresses angiogenesis induced by vascular endothelial growth factor. Biochem Biophys Res Commun. 386:374–379. 2009. View Article : Google Scholar : PubMed/NCBI

23 

Wang S, Lei T and Zhang M: The reversal effect and its mechanisms of tetramethylpyrazine on multidrug resistance in human bladder cancer. PLoS One. 11:e01577592016. View Article : Google Scholar : PubMed/NCBI

24 

Yang XG and Jiang C: Ligustrazine as a salvage agent for patients with relapsed or refractory non-Hodgkin's lymphoma. Chin Med J (Engl). 123:3206–3211. 2010.PubMed/NCBI

25 

Cao J, Miao Q, Miao S, Bi L, Zhang S, Yang Q, Zhou X, Zhang M, Xie Y, Zhang J and Wang S: Tetramethylpyrazine (TMP) exerts antitumor effects by inducing apoptosis and autophagy in hepatocellular carcinoma. Int Immunopharmacol. 26:212–220. 2015. View Article : Google Scholar : PubMed/NCBI

26 

Wang XJ, Xu YH, Yang GC, Chen HX and Zhang P: Tetramethylpyrazine inhibits the proliferation of acute lymphocytic leukemia cell lines via decrease in GSK-3β. Oncol Rep. 33:2368–2374. 2015. View Article : Google Scholar : PubMed/NCBI

27 

Chen J, Wang W, Wang H, Liu X and Guo X: Combination treatment of ligustrazine piperazine derivate DLJ14 and adriamycin inhibits progression of resistant breast cancer through inhibition of the EGFR/PI3K/Akt survival pathway and induction of apoptosis. Drug Discov Ther. 8:33–41. 2014. View Article : Google Scholar : PubMed/NCBI

28 

Pan J, Shang JF, Jiang GQ and Yang ZX: Ligustrazine induces apoptosis of breast cancer cells in vitro and in vivo. J Cancer Res Ther. 11:454–458. 2015. View Article : Google Scholar : PubMed/NCBI

29 

Mundi PS, Sachdev J, McCourt C and Kalinsky K: AKT in cancer: New molecular insights and advances in drug development. Br J Clin Pharmacol. 82:943–956. 2016. View Article : Google Scholar : PubMed/NCBI

30 

Matson DR, Hardin H, Buehler D and Lloyd RV: AKT activity is elevated in aggressive thyroid neoplasms where it promotes proliferation and invasion. Exp Mol Pathol. 103:288–293. 2017. View Article : Google Scholar : PubMed/NCBI

31 

Robert M, Frenel JS, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C and Campone M: Efficacy of buparlisib in treating breast cancer. Expert Opin Pharmacother. 18:2007–2016. 2017. View Article : Google Scholar : PubMed/NCBI

32 

Zhu L, Tian G, Yang Q, De G, Zhang Z, Wang Y, Nie H, Zhang Y, Yang X and Li J: Thyroid hormone receptor β1 suppresses proliferation and migration by inhibiting PI3K/Akt signaling in human colorectal cancer cells. Oncol Rep. 36:1419–1426. 2016. View Article : Google Scholar : PubMed/NCBI

33 

Lim W, Jeong M, Bazer FW and Song G: Coumestrol inhibits proliferation and migration of prostate cancer cells by regulating AKT, ERK1/2 and JNK MAPK cell signaling cascades. J Cell Physiol. 232:862–871. 2016. View Article : Google Scholar : PubMed/NCBI

34 

Clark PA, Bhattacharya S, Elmayan A, Darjatmoko SR, Thuro BA, Yan MB, van Ginkel PR, Polans AS and Kuo JS: Resveratrol targeting of AKT and p53 in glioblastoma and glioblastoma stem-like cells to suppress growth and infiltration. J Neurosurg. 126:1448–1460. 2016. View Article : Google Scholar : PubMed/NCBI

35 

Han XG, Du L, Qiao H, Tu B, Wang YG, Qin A, Dai KR, Fan QM and Tang TT: CXCR1 knockdown improves the sensitivity of osteosarcoma to cisplatin. Cancer Lett. 369:405–415. 2015. View Article : Google Scholar : PubMed/NCBI

36 

Yamaguchi M, Osuka S, Weitzmann MN, Shoji M and Murata T: Increased regucalcin gene expression extends survival in breast cancer patients: Overexpression of regucalcin suppresses the proliferation and metastatic bone activity in MDA-MB-231 human breast cancer cells in vitro. Int J Oncol. 49:812–822. 2016. View Article : Google Scholar : PubMed/NCBI

37 

Jiang Q, Pan Y, Cheng Y and Li H, Liu D and Li H: Lunasin suppresses the migration and invasion of breast cancer cells by inhibiting matrix metalloproteinase-2/-9 via the FAK/Akt/ERK and NF-κB signaling pathways. Oncol Rep. 36:253–262. 2016. View Article : Google Scholar : PubMed/NCBI

38 

Yang SX, Polley E and Lipkowitz S: New insights on PI3K/AKT pathway alterations and clinical outcomes in breast cancer. Cancer Treat Rev. 45:87–96. 2016. View Article : Google Scholar : PubMed/NCBI

39 

Ried SJ and Shi Y: Molecular mechanisms of caspase regulation during apoptosis. Nat Rev Mol Cell Biol. 5:897–907. 2004. View Article : Google Scholar : PubMed/NCBI

40 

Fan LL, Sun GP, Wei W, Wang ZG, Ge L, Fu WZ and Wang H: Melatonin and doxorubicin synergistically induce cell apoptosis in human hepatoma cell lines. World J Gastroenterol. 16:1473–1481. 2010. View Article : Google Scholar : PubMed/NCBI

41 

Wang L, Jin F, Qin A, Hao Y, Dong Y, Ge S and Dai K: Targeting Notch1 signaling pathway positively affects the sensitivity of osteosarcoma to cisplatin by regulating the expression and/or activity of Caspase family. Mol Cancer. 13:1392014. View Article : Google Scholar : PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Shen, J., Zeng, L., Pan, L., Yuan, S., Wu, M., & Kong, X. (2018). Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3. Oncology Letters, 15, 4557-4563. https://doi.org/10.3892/ol.2018.7851
MLA
Shen, J., Zeng, L., Pan, L., Yuan, S., Wu, M., Kong, X."Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3". Oncology Letters 15.4 (2018): 4557-4563.
Chicago
Shen, J., Zeng, L., Pan, L., Yuan, S., Wu, M., Kong, X."Tetramethylpyrazine regulates breast cancer cell viability, migration, invasion and apoptosis by affecting the activity of Akt and caspase-3". Oncology Letters 15, no. 4 (2018): 4557-4563. https://doi.org/10.3892/ol.2018.7851